Introduction/Aim. Hemophilia A is an antihemophilic factor deficiency which requires life-long treatment. The aim of this analysis was to present the effects of prophylactic non-factor replacement therapy in ten patients with hemophilia A. Patients and methods. This retrospective analysis was conducted on ten male patients (4 children, 1 adolescent, and 5 adults) with severe hemophilia A and a history of antihemophilic factor replacement prophylaxis, prior to the initiation of emicizumab prophylaxis. A single adult patient developed inhibitors during the course of factor replacement prophylaxis. Four adult patients had already developed hemophilic arthropathy before the initiation of non-factor replacement prophylaxis. Two adult patients received emicizumab prophylaxis every four weeks, while others received emicizumab every two weeks. After a 14-month period (average) of non-factor replacement prophylaxis, we analyzed the number of breakthrough bleeding episodes, annualized bleeding rate, involvement of target joints, adverse drug reactions, and interviewed the patients regarding their satisfaction with the non-factor replacement treatment. Results. None of the patients on emicizumab prophylaxis experienced breakthrough bleeding or clinical worsening of the affected target joints during the period of emicizumab prophylaxis. Annualized bleeding rate was zero in all patients on emicizumab prophylaxis. No adverse drug reactions occurred in our patients during emicizumab prophylaxis. All patients reported greater treatment satisfaction compared to the replacement prophylaxis. Conclusion. By providing safety from bleeding events and potentially the stability of the affected joints, emicizumab prophylaxis enables greater activity and increases the quality of life of treated patients.
References
1.
Laino L, Cicciù M, Fiorillo L, Crimi S, Bianchi A, Amoroso G, et al. Surgical Risk on Patients with Coagulopathies: Guidelines on Hemophiliac Patients for Oro-Maxillofacial Surgery. International Journal of Environmental Research and Public Health. 16(8):1386.
2.
Samuelson Bannow B, Recht M, Négrier C, Hermans C, Berntorp E, Eichler H, et al. Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Reviews. 2019;35:43–50.
3.
Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. Journal of Thrombosis and Haemostasis. 2023;21(3):403–12.
4.
Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A. Thrombosis and Haemostasis. 2020;120(10):1357–70.
5.
Jiménez-Yuste V, Auerswald G. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfusion.
6.
Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(S6):1–158.
7.
Berntorp E, Hermans C, Solms A, Poulsen L, Mancuso ME. Optimising prophylaxis in haemophilia A: The ups and downs of treatment. Blood Reviews. 2021;50:100852.
8.
DEN UIJL IEM, FISCHER K, VAN DER BOM JG, GROBBEE DE, ROSENDAAL FR, PLUG I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17(1):41–4.
9.
Ljung R, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, et al. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients. European Journal of Haematology. 2019;102(2):111–22.
10.
Makris M, Iorio A, Lenting PJ. Emicizumab and thrombosis: The story so far. Journal of Thrombosis and Haemostasis. 2019;17(8):1269–72.
11.
Munawar Ali R, Abid M, Zafar S, Ali MS, Nadeem R, Ahmed R, et al. Management of Severe Hemophilia A: Low-Dose Prophylaxis vs. On-Demand Treatment. Cureus. 2023;
12.
Manco-Johnson MJ, Warren BB. Long-term prophylaxis: what are our options and how to define success? Hematology. 2022;2022(1):579–85.
13.
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. New England Journal of Medicine. 2017;377(9):809–18.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
